Regeneron's lymphoma product odronextamab was authorized in the EU just months after a US rejection in 2024, followed by a recent complete response letter this year. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
